Jump to any asset
849 assets, updated daily
As of September 27, 2026, State Street SPDR S&P Biotech ETF (XBI) trades at $155.03. RSI at 36 is in neutral territory, and the price is below its 50-day average of $157.73.
State Street SPDR S&P Biotech ETF (XBI)
State Street SPDR S&P Biotech ETF NYSE
$155.03
-1.020 (-0.65%)
At close: Sep 25, 4:00 PM EDT
AI Analyst Consensus
55 / 100
The State Street SPDR S&P Biotech ETF (XBI) offers targeted exposure to the U.S. biotechnology sector, employing an equal-weighted strategy that provides balanced representation across its holdings. As of September 2026, XBI has a year-to-date return of 33.41%, significantly outperforming its category's -2.39% return. The fund's strategy aims to capture the performance of U.S. biotech equities, including drug developers and life sciences companies, across various market capitalizations. Despite recent underperformance indicated by its price being below key short-term moving averages, the fund's long-term trailing returns show strong performance, with a 1-year return of 81.71% and a 10-year return of 10.62%.
XBI Price Analysis
Market Metrics
Open
$156.80
Day Range
$153.85 to $157.17
Prev Close
$156.05
Volume
8.23M
52-Week Range
$92.64 to $169.89
XBI Fund Facts
State Street SPDR S&P Biotech ETF is an exchange-traded fund that provides targeted exposure to U.S. biotechnology companies. It seeks to track the S&P Biotechnology Select Industry Index, using an equal-weighted approach that gives relatively balanced representation across the portfolio rather than concentrating heavily in the largest firms. The fund is designed for investors looking for broad access to the biotech segment of the healthcare market through a single security.
Issuer
State Street Investment Management
Category
Health
Inception
Jan 31, 2006
Expense ratio
0.35%
Net assets
$11.40B
NAV
$156.13
Distribution yield
0.35%
YTD return
33.41%
Turnover
71.00%
Sector weights
Healthcare
99.3%
Financial Services
0.7%
Trailing returns vs category
| Period | XBI | Category |
|---|---|---|
| YTD | 33.41% | -2.39% |
| 1 month | 10.55% | 1.70% |
| 3 months | 19.00% | -3.03% |
| 1 year | 81.71% | 21.31% |
| 3 years | 27.36% | 6.58% |
| 5 years | 4.23% | 1.49% |
| 10 years | 10.62% | 8.56% |
Fund reference data as of Sep 27, 2026. Expense ratio and net assets are reported by the fund; returns are total returns and can differ from price change.
XBI Analysis
AI Technical Analysis
XBI is currently trading below its 20-day and 50-day moving averages, with the 20-day EMA at 158.32 and the 50-day SMA at 157.73, signaling short-term bearish momentum. However, the ETF remains above its 200-day SMA of 137.99, indicating that the longer-term trend is still positive. The Relative Strength Index (RSI) is at 36.29, which is in bearish territory, suggesting a lack of buying pressure. The Stochastic indicator at 23.15 also points to oversold conditions, potentially signaling a near-term bounce. The current price of 155.03 is below the 52-week range, but the 200-day SMA provides a key support level.
ProTips
- Monitor the performance of the S&P Biotechnology Select Industry Index for sector-wide trends.
- Consider the impact of regulatory news and clinical trial results on individual holdings within XBI.
- Given the sector's volatility, utilize risk management strategies such as setting stop-loss orders.
- Evaluate XBI's performance against its category averages to assess its relative strength.
- Understand that the equal-weighting methodology can lead to different performance characteristics compared to market-cap-weighted biotech ETFs.
Market Outlook
The 6-12 month outlook for XBI is cautiously optimistic, contingent on the broader biotechnology sector's performance and overall market sentiment. While the ETF is currently trading below key short-term moving averages, its position above the 200-day SMA suggests that the long-term uptrend may persist. Positive developments in drug pipelines, regulatory approvals, and a favorable macroeconomic environment could drive XBI higher. Conversely, increased regulatory scrutiny, disappointing clinical trial results, or a general market downturn could pressure the ETF's price.
Market Correlations
How this etf moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.58
Moderate correlation
Nasdaq 100 (QQQ)
+0.54
Moderate correlation
Bitcoin (BTC)
+0.31
Weak correlation
Gold (XAU)
+0.21
Weak correlation
Check Custom Correlation
How does any other asset move with XBI? One year of daily closes, Pearson correlation.
Try
Key Statistics
| Yield | 0.35% |
|---|---|
| Day High | $157.17 |
| Day Low | $153.85 |
| 52 Week High | 169.89 |
| 52 Week Low | 92.64 |
The State Street SPDR S&P Biotech ETF (XBI) is heavily concentrated in the Healthcare sector, with 99.28% of its assets allocated to this industry. The fund's equal-weighting methodology ensures that smaller biotechnology companies have a meaningful impact on performance, differentiating it from market-cap-weighted indices. The sector's performance has been volatile, as evidenced by the mixed trailing returns against its category. The fund's expense ratio is 0.35%, costing $35.00 per $10,000 invested, and it holds net assets of $11.40 billion. The high concentration in biotechnology presents both opportunities for significant growth and risks associated with sector-specific headwinds.
Earnings & Growth Analysis
The underlying biotechnology companies it holds are subject to the dynamic earnings environment of the healthcare sector. The sector's performance is often driven by drug trial results, regulatory approvals, and patent expirations, which can lead to significant stock price movements. The broad exposure of XBI means its aggregate performance reflects the overall health and innovation pipeline within the U.S. biotechnology industry. Investors should monitor the earnings trends of major biotech firms to gauge the sector's overall profitability and growth prospects.
Key Risks
The primary risk for XBI is its high concentration in the biotechnology sector, making it susceptible to sector-specific downturns driven by regulatory changes, clinical trial failures, or shifts in healthcare policy. The equal-weighting approach also means that the failure of a few significant holdings could disproportionately impact the ETF's performance compared to a market-cap-weighted fund. Also, the biotech sector is known for its high volatility, which can lead to significant price swings.
Technical Indicators
| RSI (14) | 36.29 |
|---|---|
| MACD | -0.94 |
| SMA 50 | 157.73 |
| SMA 200 | 137.99 |
RSI
Bearish
SMA Cross
Bullish
Price vs SMA
Bearish
MACD
Bearish
Golden Cross in effect with the 50-day SMA ($157.73) above the 200-day SMA ($137.99), price is trading below the 50-day SMA.
XBI Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies pick an entry style
Conservative
$153.48
Slight discount to current
Wait for small dip
Aggressive
$155.03
At current price
Enter now if confident
Risk Management
STOP LOSS
$148.51
MAX LOSS
-3.2%
Volatility-Adjusted Stop Loss
Calculated based on RSI (36.3) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$158.08
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$161.15
+5% (Conservative)
+3.9% (Aggressive)
TARGET 3
$165.76
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
ETF Investment Disclaimer
This AI-generated analysis of XBI is for educational purposes only and does not constitute investment advice. ETFs are subject to market risk including possible loss of principal. Performance depends on the underlying index or assets tracked. Read the fund prospectus before investing. Past performance does not guarantee future results. Generated on September 27, 2026.Growth of $10,000
A $10,000 investment in XBI in September 2016 would be worth about $22,550 today, compared with about $35,782 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in XBI today could grow to about $21,295 by 2036 in the base case, with a bull case near $77,834 and a bear case around $5,826. Projections are statistical simulations, not guarantees.
XBI ETF Price Prediction: 2030
CleaRank's simulation projects a price near $210 for XBI by 2030 in the base case, from $155 today (1.4x over 4 years). The downside path ends near $92.41. These are outcomes of a Monte Carlo simulation run on XBI's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $111 | $167 | $252 |
| 2028 | $101 | $180 | $322 |
| 2029 | $95.63 | $194 | $396 |
| 2030 | $92.41 | $210 | $476 |
| 2031 | $90.48 | $226 | $566 |
| 2032 | $89.41 | $244 | $666 |
| 2033 | $88.98 | $263 | $778 |
| 2034 | $89.04 | $284 | $905 |
| 2035 | $89.51 | $306 | $1,047 |
| 2036 | $90.33 | $330 | $1,207 |
Method: 10,000 simulated price paths using XBI's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
Frequently Asked Questions
What is the expense ratio for the State Street SPDR S&P Biotech ETF (XBI)?
The expense ratio for XBI is 0.35%, which translates to a cost of $35.00 per $10,000 invested annually. This fee covers the management and operational costs of the fund.
What sectors does the State Street SPDR S&P Biotech ETF (XBI) hold?
XBI is heavily concentrated in the Healthcare sector, holding 99.28% of its assets in this industry. A small portion, 0.72%, is allocated to Financial Services.
How has the State Street SPDR S&P Biotech ETF (XBI) performed against its category?
XBI has shown strong performance relative to its category, particularly over longer periods. For example, its 1-year return was 81.71% compared to the category's 21.31%, and its 10-year return was 10.62% versus the category's 8.56%.
What is the price prediction for XBI ETF in 2030?
Based on Monte Carlo simulations, the projected base price for XBI in 2030 is $209.76, with a downside price of $92.41 and an upside price of $476.13. These figures represent statistical simulation outcomes, not guaranteed price targets.
What are the key technical levels for XBI?
XBI is currently trading below its 20-day and 50-day moving averages, indicating short-term weakness. The 200-day moving average at $137.99 serves as a key support level, while the 50-day SMA at $157.73 acts as a resistance level.
What is the dividend yield for XBI?
The dividend yield for XBI is approximately 0.35%, providing a modest income stream to investors. The annual dividend rate is $0.54.
How diversified is the State Street SPDR S&P Biotech ETF (XBI)?
XBI is not broadly diversified as it is highly concentrated in the biotechnology segment of the healthcare sector, holding 99.28% of its assets within this industry. Its equal-weighting strategy provides diversification across various biotech companies rather than across different sectors.
What is the current RSI status for XBI?
The current RSI for XBI is 36.29, which is interpreted as bearish momentum, indicating a lack of strong buying interest in the ETF.